Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical's primary product, the 3D bunion correction system "Lapiplasty," faced decreased demand due to competition [2]. - It is alleged that Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [2]. - Defendants are accused of making misleading positive statements regarding the company's business and prospects, lacking a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

If you purchased or acquired Treace Medical securities, and/or would like to discuss your legal rights and options please visit Treace Medical Concepts, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com. According to the Complaint, Defendants made misrepresentations concerning the impact of competition on demand for, and utilization of, the Company's primary product, the Lapiplasty 3D Bunion Correction System. If you wish to ...

Group 1 - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI) regarding a class action lawsuit for shareholders who purchased shares during the class period from May 8, 2023, to May 7, 2024 [1] - The allegations in the complaint include that competition negatively affected the demand for Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty," leading to a decline in revenue [1] - The company was required to accelerate plans to introduce an alternative product to osteotomy due to the decline in revenue and the misleading positive statements made by the defendants regarding the company's business and prospects [1] Group 2 - Shareholders are encouraged to register for the class action by June 10, 2025, to potentially become lead plaintiffs and participate in the case without any cost or obligation [2] - Once registered, shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [3]

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc." or the "Company") (NASDAQ: TMCI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Treace Medical Concepts, Inc. investors who were adversely affected by alleged securities fraud between May 8, 2023 and May 7, 2024. Follow the link below to get more information and be contacted by a member of our team: htt ...

NEW YORK, May 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc." or the "Company") (NASDAQ: TMCI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Treace Medical Concepts, Inc. investors who were adversely affected by alleged securities fraud between May 8, 2023 and May 7, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zl ...

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI). Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=146184&from=3 ...

Core Viewpoint - Treace Medical Concepts, Inc. (NASDAQ: TMCI) is facing allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty," which has led to a decline in revenue and necessitated a shift in product strategy [1][2]. Group 1: Allegations and Impact - The complaint alleges that competition has negatively impacted the demand and utilization of the "Lapiplasty" system [1]. - As a result of the competitive pressures, Treace Medical's revenue has declined, prompting the company to accelerate plans for an alternative product to osteotomy [1]. - The defendants' positive statements about the company's business and prospects were found to be materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased TMCI shares during the class period from May 8, 2023, to May 7, 2024, are encouraged to register for the class action [2]. - The deadline for shareholders to seek lead plaintiff status is June 10, 2025, and there is no cost or obligation to participate in the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Investors in Treace Medical Concepts, Inc. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed competitive impacts on the company's primary product and misleading statements from the defendants [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from May 8, 2023, to May 7, 2024, Treace Medical's defendants failed to disclose that competition affected the demand and utilization of the Lapiplasty 3D Bunion Correction System [2] - As a result of competitive pressures, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2] - The defendants' positive statements regarding the company's business and prospects were materially misleading and lacked a reasonable basis during the relevant period [2] Participation Information - Investors who suffered losses in Treace Medical are encouraged to participate in the ongoing securities fraud lawsuit before the lead plaintiff deadline of June 10, 2025 [2] - Interested parties can contact the Law Offices of Frank R. Cruz for more information on participation [3][4]

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1] Group 1: Lawsuit Details - The lawsuit claims that Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty," faced decreased demand and utilization due to competition [2] - As a result of the competition, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [2] - The defendants allegedly made misleading positive statements regarding the company's business, operations, and future prospects [2] Group 2: Next Steps for Investors - Investors who experienced losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be eligible for compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]